Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 2/2010

01.03.2010

The Pathogenesis and Treatment of the Valvulopathy of Aortic Stenosis: Beyond the SEAS

verfasst von: Sammy Elmariah, Emile R. Mohler III

Erschienen in: Current Cardiology Reports | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Fibrocalcific aortic stenosis (AS) results from an active process similar to atherosclerosis that involves basement membrane disruption, lipid deposition, inflammatory cell infiltration, and calcification. Consequently, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have been extensively studied as potential therapeutic agents capable of slowing the progression of AS. However, two randomized trials, SALTIRE and the SEAS study, showed no benefit with statin therapy for AS. These results have shed doubt over the efficacy of statin therapy for AS, although their potential efficacy at early stages of aortic valve disease remains possible. In this article, we review the pathophysiology of fibrocalcific AS and discuss future directions for its nonsurgical management in the post-SEAS era.
Literatur
1.
• Goldbarg SH, Elmariah S, Miller MA, Fuster V: Insights into degenerative aortic valve disease. J Am Coll Cardiol 2007, 50:1205–1213. This is an informative review of degenerative aortic valve disease pathophysiology and therapeutic options.
2.
• Rajamannan NM: Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 2009, 29:162–168. This is a thorough review highlighting all experimental models of AS.
3.
O’Brien KD: Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006, 26:1721–1728.CrossRefPubMed
4.
Stritzke J, Linsel-Nitschke P, Markus MR, et al.: Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey. Eur Heart J 2009, 30:2044–2053.CrossRefPubMed
5.
Stewart BF, Siscovick D, Lind BK, et al.: Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997, 29:630–634.CrossRefPubMed
6.
Mohler ER 3rd, Gannon F, Reynolds C, et al.: Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522–1528.PubMed
7.
• Moura LM, Ramos SF, Zamorano JL, et al.: Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007, 49:554–561. This is the only prospective study to demonstrate beneficial effect of statins on AS progression.
8.
Cowell SJ, Newby DE, Prescott RJ, et al.: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389–2397.CrossRefPubMed
9.
•• Rossebø AB, Pedersen TR, Boman K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343–1356. This is a large, randomized clinical trial that failed to show a benefit of statin therapy on AS progression.
10.
Thom T, Haase N, Rosamond W, et al.: Heart disease and stroke statistics–2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113:e85–e151.CrossRefPubMed
11.
Otto CM, Lind BK, Kitzman DW, et al.: Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999, 341:142–147.CrossRefPubMed
12.
Ix JH, Shlipak MG, Katz R, et al.: Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2007, 50:412–420.CrossRefPubMed
13.
Katz R, Wong ND, Kronmal R, et al.: Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006, 113:2113–2119.CrossRefPubMed
14.
Owens DS, Katz R, Johnson E, et al.: Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Arch Intern Med 2008, 168:1200–1207.CrossRefPubMed
15.
Rajamannan NM, Bonow RO, Rahimtoola SH: Calcific aortic stenosis: an update. Nat Clin Pract Cardiovasc Med 2007, 4:254–262.CrossRefPubMed
16.
Caira FC, Stock SR, Gleason TG, et al:. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006, 47:1707–1712.CrossRefPubMed
17.
Kaden JJ, Bickelhaupt S, Grobholz R, et al.: Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004, 13:560–566.PubMed
18.
•• Aikawa E, Nahrendorf M, Figueiredo JL, et al.: Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 2007, 116:2841–2850. This paper discussed using a novel near-infrared fluorescent nanoparticle to image early stages of vascular and valvular calcification.
19.
Aikawa E, Aikawa M, Libby P, et al.: Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 2009, 119:1785–1794.CrossRefPubMed
20.
Meng X, Ao L, Song Y, et al.: Expression of functional toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis. Am J Physiol Cell Physiol 2008, 294:C29–C35.CrossRefPubMed
21.
Yang X, Fullerton DA, Su X, et al.: Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J Am Coll Cardiol 2009, 53:491–500.CrossRefPubMed
22.
Osman L, Chester AH, Sarathchandra P, et al.: A novel role of the sympatho-adrenergic system in regulating valve calcification. Circulation 2007, 116:I282–I287.CrossRefPubMed
23.
Helske S, Oksjoki R, Lindstedt KA, et al.: Complement system is activated in stenotic aortic valves. Atherosclerosis 2008, 196:190–200.CrossRefPubMed
24.
Liberman M, Bassi E, Martinatti MK, et al.: Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol 2008, 28:463–470.CrossRefPubMed
25.
Miller JD, Chu Y, Brooks RM, et al.: Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008, 52:843–850.CrossRefPubMed
26.
Miller JD, Weiss RM, Serrano KM, et al.: Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 2009, 119:2693–2701.CrossRefPubMed
27.
Garg V, Muth AN, Ransom JF, et al.: Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437:270–274.CrossRefPubMed
28.
Nigam V, Srivastava D: Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol 2009, 47:828–834.CrossRefPubMed
29.
Tkatchenko T, Moreno-Rodriguez R, Conway S, et al.: Lack of periostin leads to suppression of Notch1 signaling and calcific aortic valve disease. Physiol Genomics 2009, 39:160–168.CrossRefPubMed
30.
• Bosse Y, Mathieu P, Pibarot P: Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis. J Am Coll Cardiol 2008, 51:1327–1336. This is an informative review highlighting genetic mutations that have been associated with AS.
31.
Antonini-Canterin F, Hirsu M, Popescu BA, et al.: Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008, 102:738–742.CrossRefPubMed
32.
Mohty D, Pibarot P, Despres JP, et al.: Age-related differences in the pathogenesis of calcific aortic stenosis: the potential role of resistin. Int J Cardiol 2009 Jan 20 (Epub ahead of print).
33.
Choi BG, Vilahur G, Yadegar D, et al.: The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med 2006, 6:571–587.CrossRefPubMed
34.
Busseuil D, Shi Y, Mecteau M, et al.: Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits. Br J Pharmacol 2008, 154:765–773.CrossRefPubMed
35.
Cimmino G, Speidl WS, Ibanez B, et al.: oxLDL Induces the expression of MCP-1 in aortic valve myofibroblasts via activation of NF-kappa B—inhibitory effects of recombinant Apo AI-Milano [abstract 1043–227]. J Am Coll Cardiol 2009, 53:A415.
36.
Ertas FS, Hasan T, Ozdol C, et al.: Relationship between angiotensin-converting enzyme gene polymorphism and severity of aortic valve calcification. Mayo Clin Proc 2007, 82:944–950.CrossRefPubMed
37.
Simolin MA, Pedersen TX, Bro S, et al.: ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model. BMC Cardiovasc Disord 2009, 9:10.CrossRefPubMed
38.
Cote N, Pibarot P, Pepin A, et al.: Oxidized low-density lipoprotein, angiotensin II and increased waist circumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. Int J Cardiol 2009 Jun 12 (Epub ahead of print).
39.
Corrado A, Santoro N, Cantatore FP: Extra-skeletal effects of bisphosphonates. Joint Bone Spine 2007, 74:32–38.CrossRefPubMed
40.
Adami S, Braga V, Guidi G, et al.: Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 2000, 15:599–604.CrossRefPubMed
41.
Montagnani A, Gonnelli S, Cepollaro C, et al.: Changes in serum HDL and LDL cholesterol in patients with Paget’s bone disease treated with pamidronate. Bone 2003, 32:15–19.CrossRefPubMed
42.
Price PA, Faus SA, Williamson MK: Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001, 21:817–824.CrossRefPubMed
43.
Rapoport HS, Connolly JM, Fulmer J, et al.: Mechanisms of the in vivo inhibition of calcification of bioprosthetic porcine aortic valve cusps and aortic wall with triglycidylamine/mercapto bisphosphonate. Biomaterials 2007, 28:690–699.CrossRefPubMed
44.
Elmariah S, O’Brien KD, Budoff MJ, et al.: The relationship of bisphosphonate use to the prevalence of aortic valve calcification in women. The Multi-Ethnic Study of Atherosclerosis [abstract 1001–299]. J Am Coll Cardiol 2009, 53:A461.CrossRef
45.
Skolnick AH, Osranek M, Formica P, Kronzon I: Osteoporosis treatment and progression of aortic stenosis. Am J Cardiol 2009, 104:122–124.CrossRefPubMed
46.
Poon M, Badimon JJ, Fuster V: Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet 2002, 359:619–622.CrossRefPubMed
47.
Wessely R, Schomig A, Kastrati A: Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol 2006, 47:708–714.CrossRefPubMed
48.
Olsson M, Rosenqvist M, Nilsson J: Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis. J Am Coll Cardiol 1994, 24:1664–1671.PubMedCrossRef
49.
Spargias K, Milewski K, Debinski M, et al:. Drug delivery at the aortic valve tissues of healthy domestic pigs with a Paclitaxel-eluting valvuloplasty balloon. J Interv Cardiol 2009, 22:291–298.CrossRefPubMed
50.
• Zajarias A, Cribier AG: Outcomes and safety of percutaneous aortic valve replacement. J Am Coll Cardiol 2009, 53:1829–1836. This is a recent review summarizing patient outcomes and safety with percutaneous aortic valve replacement.
Metadaten
Titel
The Pathogenesis and Treatment of the Valvulopathy of Aortic Stenosis: Beyond the SEAS
verfasst von
Sammy Elmariah
Emile R. Mohler III
Publikationsdatum
01.03.2010
Verlag
Current Science Inc.
Erschienen in
Current Cardiology Reports / Ausgabe 2/2010
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-010-0089-6

Weitere Artikel der Ausgabe 2/2010

Current Cardiology Reports 2/2010 Zur Ausgabe

ReviewPaper

Mitral Valve Repair: What the ACORN Trial Taught Us

ReviewPaper

Low-Flow, Low-Gradient, Normal Ejection Fraction Aortic Stenosis

ReviewPaper

The Use of Nuclear Imaging for Cardiac Resynchronization Therapy

ReviewPaper

The Pathogenesis of Aortopathy in Marfan Syndrome and Related Diseases

ReviewPaper

Screening Asymptomatic Patients with Type 2 Diabetes Mellitus for Coronary Artery Disease: Does It Improve Patient Outcome?

ReviewPaper

Does Myocardial Perfusion Imaging Provide Incremental Prognostic Information to Left Ventricular Ejection Fraction?

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise